SNPX Logo

Synaptogenix, Inc. (SNPX) 

NASDAQ
Market Cap
$4M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
722 of 776
Rank in Industry
395 of 433

Largest Insider Buys in Sector

SNPX Stock Price History Chart

SNPX Stock Performance

About Synaptogenix, Inc.

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; …

Insider Activity of Synaptogenix, Inc.

Over the last 12 months, insiders at Synaptogenix, Inc. have bought $0 and sold $0 worth of Synaptogenix, Inc. stock.

On average, over the past 5 years, insiders at Synaptogenix, Inc. have bought $165,600 and sold $190,375 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $83,000 was made by Silverman Joshua (director) on 2021‑06‑14.

List of Insider Buy and Sell Transactions, Synaptogenix, Inc.

2022-12-16Saledirector
19,012
0.2656%
$1.17$22,280-30.83%
2022-12-16SalePresident and CSO
19,688
0.2751%
$1.17$23,072-30.83%
2022-12-16SaleChief Financial Officer
27,000
0.3773%
$1.17$31,641-30.83%
2022-12-16SaleChief Executive Officer
27,000
0.3773%
$1.17$31,641-30.83%
2022-12-16Saledirector
27,000
0.3773%
$1.17$31,641-30.83%
2022-12-16Saledirector
20,250
0.2829%
$1.17$23,731-30.83%
2022-12-16Saledirector
22,500
0.3144%
$1.17$26,368-30.83%
2021-06-14Purchasedirector
10,000
0.2577%
$8.30$83,000-3.58%
2021-06-14PurchaseChief Scientific Officer
10,000
0.2565%
$8.26$82,600-3.58%

Insider Historical Profitability

<0.0001%
Silverman Joshuadirector
38238
2.8207%
$2.9511<0.0001%
Alkon Daniel L.President and CSO
35546
2.6221%
$2.9511<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.